Inhibition of Fatty Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Fatty acid synthase, a key enzyme of de novo lipogenesis, is an attractive therapeutic target in cancer. The novel fatty acid synthase inhibitor, TVB-3664, shows anti-cancer activity in multiple cancers including colorectal cancer; however, it is unclear whether uptake of exogeneous fatty acids can compensate for the effect of fatty acid synthase inhibition. This study demonstrates that inhibition of fatty acid synthase selectively upregulates fatty acid translocase (CD36), a fatty acid transporter, in multiple colorectal cancer models including colorectal cancer cells with shRNA mediated knockdown of fatty acid synthase and genetically modified mouse tissues with heterozygous and homozygous deletion of fatty acid synthase. Furthermore, human colorectal cancer tissues treated with TVB-3664 show a significant and selective upregulation of CD36 mRNA. shRNA-mediated knockdown of CD36 and inhibition of CD36 via sulfosuccinimidyl oleate, a chemical inhibitor of CD36, decreased cell proliferation in vitro and reduced tumor growth in subcutaneous xenograft models. Isogenic cell populations established from patient derived xenografts and expressing high levels of CD36 show a significantly increased ability to grow tumors in vivo. The tumor-promoting effect of CD36 is associated with an increase in the levels of pAkt and survivin. Importantly, combinatorial treatment of primary and established colorectal cancer cells with TVB-3664 and sulfosuccinimidyl oleate shows a synergistic effect on cell proliferation. In summary, our study demonstrates that upregulation of CD36 expression is a potential compensatory mechanism for fatty acid synthase inhibition and that inhibition of CD36 can improve the efficacy of fatty acid synthase-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 2×
“Inhibition of FASN and CD36 in Combination Reduce Primary CRC Cell Proliferation in vitro Both de novo synthesized and exogenous FA play important roles in carcinogenesis (28, 39), To extend our findings that FASN inhibition upregulates the expression of CD36 and to further test whether inhibition of CD36 can improve…”
BackgroundMethodFatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Since cancer cells utilize both endogenously-synthesized lipids and exogeneous fatty acids (25), and our published data indicate that an enhanced uptake of dietary fatty acids may be a potential mechanism of resistance to FASN inhibitors (10), the goal of this study was to evaluate the interconnection between these tw…”
BackgroundCellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 1×
“While most tumors exhibit a shift toward FA synthesis, they can also scavenge lipids from their environment (4).”
BackgroundTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · cited 1×
“Furthermore, the mutational and metabolic profiles of tumors determine tumor cell response to multiple therapies including metabolic inhibitors (48, 49).”
BackgroundVentura, R., Mordec, K., Waszczuk, J., Wang, Z., Lai, J., Fridlib, M., Buckley, D., Kemble, G., & Heuer, T. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.020 · Cited by 301
Zaytseva, Y. Y., Rychahou, P. G., Gulhati, P., Elliott, V. A., Mustain, W. C., O'Connor, K., Morris, A. J., Sunkara, M., Weiss, H. L., Lee, E. Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4057 · Cited by 208
Self-citationHeuer, T. S., Ventura, R., Mordec, K., Lai, J., Fridlib, M., Buckley, D., & Kemble, G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.012 · Cited by 136
Zaytseva, Y. Y., Rychahou, P. G., Le, A.-T., Scott, T. L., Flight, R. M., Kim, J. T., Harris, J., Liu, J., Wang, C., Morris, A. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25361 · Cited by 123 · cited 9×
“Since cancer cells utilize both endogenously-synthesized lipids and exogeneous fatty acids (25), and our published data indicate that an enhanced uptake of dietary fatty acids may be a potential mechanism of resistance to FASN inhibitors (10), the goal of this study was to evaluate the interconnection between these tw…”
BackgroundMethodSelf-citation
Cited by
The role of lipids in cancer progression and metastasis
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 563
Drury, J., Rychahou, P. G., Kelson, C. O., Geisen, M. E., Wu, Y., He, D., Wang, C., Lee, E. Y., Evers, B. M., & Zaytseva, Y. Y. (2022) · Cancers · doi:10.3390/cancers14010252 · Cited by 64
“Recently, our laboratory has shown the important role of CD36 in enhancing cellular proliferation and progression of primary CRC and identified upregulation of CD36 as a potential mechanism of resistance to FASN-targeted therapy [15].”
BackgroundResultInfluentialSelf-citationLipid metabolism as a targetable metabolic vulnerability in colorectal cancer
Zaytseva, Y. (2021) · Cancers · doi:10.3390/cancers13020301 · Cited by 53
“Interestingly, upregulation of CD36 has been shown to be a potential compensatory mechanism that drives resistance to TVB-3664, a novel inhibitor of FASN, which potentially suggests that simultaneous inhibition of FA uptake and synthesis would be required to achieve a desirable anticancer effect in CRC [43].”
BackgroundSelf-citationMa, Y., Nenkov, M., Chen, Y., & Gaßler, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158352 · Cited by 28
“…inflammation in CRC cell lines [279–281] Antagonist (SSO) Inhibits cell migration in hepatocellular carcinoma and reduces cell proliferation in CRC [282 Upregulated lipid trafficking proteins are observed in adipose tissue as well as in different cancer types, including CRC. Increased lipid uptake…”
Background
Metadata
- Authors
- Drury, J., Rychahou, P. G., He, D., Jafari, N., Wang, C., Lee, E. Y., Weiss, H. L., Evers, B. M., & Zaytseva, Y. Y.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-31
- Volume
- 10
- Pages
- 1185-1185
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3045830102
- Cited by
- 110
- References
- 10
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Fatty Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells. https://app.cochat.ai/papers/10.3389/fonc.2020.01185
- The paper
- Drury, J., Rychahou, P. G., He, D., Jafari, N., Wang, C., Lee, E. Y., Weiss, H. L., Evers, B. M., & Zaytseva, Y. Y. (2020). Inhibition of Fatty Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.01185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.